Genes regulated in metastatic osteosarcoma: Evaluation by microarray analysis in four human and two mouse cell line systems

Sarcoma

Volumn 2012, Issue , 2012, Pages

  Muff, Roman ^a   Ram Kumar, Ram Mohan ^a   Botter, Sander M ^a   Born, Walter ^a   Fuchs, Bruno ^a  

^a BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; METASTASIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OSTEOSARCOMA; PHENOTYPE; PRIORITY JOURNAL;

EID: 84871372983     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2012/937506     Document Type: Article

References (89)

1. Jia S. F., Worth L. L., Kleinerman E. S., A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clinical and Experimental Metastasis 1999 17 6 501 506 2-s2.0-0033504341 10.1023/A:1006623001465 (Pubitemid 30182744)
2. Kimura K., Nakano T., Park Y. B., Tani M., Tsuda H., Beppu Y., Moriya H., Yokota J., Establishment of human osteosarcoma cell lines with high metastatic potential to lungs and their utilities for therapeutic studies on metastatic osteosarcoma. Clinical and Experimental Metastasis 2002 19 6 477 485 2-s2.0-0036396794 10.1023/A:1020395816633 (Pubitemid 35178665)
3. Rhim J. S., Cho H. Y., Huebner R. J., Non producer human cells induced by murine sarcoma virus. International Journal of Cancer 1975 15 1 23 29 2-s2.0-0016440994
4. Shi X. B., Chen A. M., Cai X. H., Guo F. J., Liao G. N., Ma D., Establishment and characterization of cell sublines with high and low metastatic potential derived from human osteosarcoma. Chinese Medical Journal 2005 118 8 687 690 2-s2.0-17844392885 (Pubitemid 40585032)
5. Asai T., Ueda T., Itoh K., Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. International Journal of Cancer 1998 76 3 418 422 (Pubitemid 28282943)
6. Khanna C., Prehn J., Yeung C., Caylor J., Tsokos M., Helman L., An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clinical and Experimental Metastasis 2000 18 3 261 271 2-s2.0-0035057571 10.1023/A:1006767007547 (Pubitemid 32269996)
7. Nakano T., Tani M., Ishibashi Y., Kimura K., Park Y. B., Imaizumi N., Tsuda H., Aoyagi K., Sasaki H., Ohwada S., Yokota J., Biological properties and gene expression associated with metastatic potential of human osteosarcoma. Clinical and Experimental Metastasis 2003 20 7 665 674 2-s2.0-0345304776 10.1023/A:1027355610603 (Pubitemid 37463904)
8. Khanna C., Khan J., Nguyen P., Prehn J., Caylor J., Yeung C., Trepel J., Meltzer P., Helman L., Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Research 2001 61 9 3750 3759 2-s2.0-0035328785 (Pubitemid 32694989)
9. Flores R. J., Li Y., Yu A., A systems biology approach reveals common metastatic pathways in osteosarcoma. BMC Systems Biology 2012 6 1 50
10. Curto M., McClatchey A. I., Ezrin. A metastatic detERMinant? Cancer Cell 2004 5 2 113 114 2-s2.0-1442334887 10.1016/S1535-6108(04)00031-5 (Pubitemid 38283796)
11. Martin J. W., Zielenska M., Stein G. S., Squire J. A., van Wijnen A. J., The role of RUNX2 in osteosarcoma oncogenesis. Sarcoma 2011 2011 13 2-s2.0-79251553733 10.1155/2011/282745 282745
12. Stephens P. J., Greenman C. D., Fu B., Yang F., Bignell G. R., Mudie L. J., Pleasance E. D., Lau K. W., Beare D., Stebbings L. A., McLaren S., Lin M. L., McBride D. J., Varela I., Nik-Zainal S., Leroy C., Jia M., Menzies A., Butler A. P., Teague J. W., Quail M. A., Burton J., Swerdlow H., Carter N. P., Morsberger L. A., Iacobuzio-Donahue C., Follows G. A., Green A. R., Flanagan A. M., Stratton M. R., Futreal P. A., Campbell P. J., Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011 144 1 27 40 2-s2.0-78650959663 10.1016/j.cell.2010.11.055
13. Bacci G., Bertoni F., Longhi A., Ferrari S., Forni C., Biagini R., Bacchini P., Donati D., Manfrini M., Bernini G., Lari S., Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity: histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer 2003 97 12 3068 3075 2-s2.0-0038052287 10.1002/cncr.11456 (Pubitemid 36676262)
14. Muff R., Nigg N., Gruber P., Walters D., Born W., Fuchs B., Altered morphology, nuclear stability and adhesion of highly metastatic derivatives of osteoblast-like SAOS-2 osteosarcoma cells. Anticancer Research 2007 27 6 3973 3979 2-s2.0-37549033087
15. Chipoy C., Berreur M., Couillaud S., Pradal G., Vallette F., Colombeix C., Rédini F., Heymann D., Blanchard F., Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3. Journal of Bone and Mineral Research 2004 19 11 1850 1861 2-s2.0-16644401857 10.1359/JBMR.040817 (Pubitemid 41103437)
16. Schmidt J., Strauss G. P., Schon A., Luz A., Murray A. B., Melchiori A., Aresu O., Erfle V., Establishement and characterization of osteogenic cell lines from a spontaneous murine osteosarcoma. Differentiation 1988 39 3 151 160 2-s2.0-0024166354 (Pubitemid 19082658)
17. Husmann K., Muff R., Bolander M. E., Sarkar G., Born W., Fuchs B., Cathepsins and osteosarcoma: expression analysis identifies cathepsin K as an indicator of metastasis. Molecular Carcinogenesis 2008 47 1 66 73 2-s2.0-38349023103 10.1002/mc.20362
18. Long F., Building strong bones: molecular regulation of the osteoblast lineage. Nature Reviews Molecular Cell Biology 2012 13 1 27 38
19. Dass C. R., Nadesapillai A. P. W., Robin D., Howard M. L., Fisher J. L., Zhou H., Choong P. F. M., Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma. Clinical and Experimental Metastasis 2005 22 8 643 652 2-s2.0-33747473703 10.1007/s10585-006-9004-3 (Pubitemid 44259525)
20. Fuchs B., Zhang K., Bolander M. E., Sarkar G., Identification of differentially expressed genes by mutually subtracted RNA fingerprinting. Analytical Biochemistry 2000 286 1 91 98 2-s2.0-0034326786 10.1006/abio.2000. 4792
21. Wiggan O., Hamel P. A., Pax3 regulates morphogenetic cell behavior in vitro coincident with activation of a PCP/non-canonical Wnt-signaling cascade. Journal of Cell Science 2002 115 3 531 541 2-s2.0-0036473410 (Pubitemid 34182980)
22. Wiggan O., Fadel M. P., Hamel P. A., Pax3 induces cell aggregation and regulates phenotypic mesenchymal-epithelial interconversion. Journal of Cell Science 2002 115 3 517 529 2-s2.0-0036472493 (Pubitemid 34182979)
23. Kloen P., Gebhardt M. C., Perez-Atayde A., Expression of transforming growth factor-beta (TGF-beta) isoforms in osteosarcomas: TGF-beta3 is related to disease progression. Cancer 1997 80 12 2230 2239 (Pubitemid 28007393)
24. Paoloni M., Davis S., Lana S., Withrow S., Sangiorgi L., Picci P., Hewitt S., Triche T., Meltzer P., Khanna C., Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics 2009 10, article 625 2-s2.0-77449128013 10.1186/1471-2164-10-625
25. Chipoy C., Brounais B., Trichet V., Battaglia S., Berreur M., Oliver L., Juin P., Rédini F., Heymann D., Blanchard F., Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53. Oncogene 2007 26 46 6653 6664 2-s2.0-35348850681 10.1038/sj.onc.1210492 (Pubitemid 47573687)
26. Brounais B., Chipoy C., Mori K., Charrier C., Battaglia S., Pilet P., Richards C. D., Heymann D., Rédini F., Blanchard F., Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the antitumor effect of midostaurin in vivo. Clinical Cancer Research 2008 14 17 5400 5409 2-s2.0-53049108932 10.1158/1078-0432.CCR-07-4781
27. Huang Y., Dai H., Guo Q. N., TSSC3 overexpression reduces stemness and induces apoptosis of osteosarcoma tumor-initiating cells. Apoptosis 2012 17 8 749 761
28. Dai H., Huang Y., Li Y., Meng G., Wang Y., Guo Q. N., TSSC3 overexpression associates with growth inhibition, apoptosis induction and enhances chemotherapeutic effects in human osteosarcoma. Carcinogenesis 2012 33 1 30 40
29. Halder S. K., Cho Y. J., Datta A., Elucidating the mechanism of regulation of transforming growth factor beta Type II receptor expression in human lung cancer cell lines. Neoplasia 2011 13 10 912 922
30. Crijns A. P. G., de Graeff P., Geerts D., ten Hoor K. A., Hollema H., van der Sluis T., Hofstra R. M. W., de Bock G. H., de Jong S., van der Zee A. G. J., de Vries E. G. E., MEIS and PBX homeobox proteins in ovarian cancer. European Journal of Cancer 2007 43 17 2495 2505 2-s2.0-36048982511 10.1016/j.ejca.2007.08.025 (Pubitemid 350086934)
31. Vriens M. R., Moses W., Weng J., Peng M., Griffin A., Bleyer A., Pollock B. H., Indelicato D. J., Hwang J., Kebebew E., Clinical and molecular features of papillary thyroid cancer in adolescents and young adults. Cancer 2011 117 2 259 267 2-s2.0-78650988256 10.1002/cncr.25369
32. Chen J. L., Li J., Kiriluk K., Deregulation of a hox protein regulatory network spanning prostate cancer initiation and progression. Clinical Cancer Research 2012 18 16 4291 4302
33. Bouton M. C., Boulaftali Y., Richard B., Arocas V., Michel J. B., Jandrot-Perrus M., Emerging role of serpinE2/protease nexin-1 in hemostasis and vascular biology. Blood 2012 119 11 2452 2457
34. Xu D., McKee C. M., Cao Y., Ding Y., Kessler B. M., Muschel R. J., Matrix metalloproteinase-9 regulates tumor cell invasion through cleavage of protease nexin-1. Cancer Research 2010 70 17 6988 6998 2-s2.0-77956291596 10.1158/0008-5472.CAN-10-0242
35. Buchholz M., Biebl A., Neeße A., Wagner M., Iwamura T., Leder G., Adler G., Gress T. M., SERPINE2 (protease nexin I) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo. Cancer Research 2003 63 16 4945 4951 2-s2.0-0042440692 (Pubitemid 37022630)
36. Bergeron S., Lemieux E., Durand V., Cagnol S., Carrier J. C., Lussier J. G., Boucher M. J., Rivard N., The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis. Molecular Cancer 2010 9, article 271 2-s2.0-77957724105 10.1186/1476-4598-9-271
37. Selzer-Plon J., Bornholdt J., Friis S., Bisgaard H. C., Lothe I. M. B., Tveit K. M., Kure E. H., Vogel U., Vogel L. K., Expression of prostasin and its inhibitors during colorectal cancer carcinogenesis. BMC Cancer 2009 9, article 201 2-s2.0-68349152439 10.1186/1471-2407-9-201
38. Candia B. J., Hines W. C., Heaphy C. M., Griffith J. K., Orlando R. A., Protease nexin-1 expression is altered in human breast cancer. Cancer Cell International 2006 6, article 16 2-s2.0-33746085972 10.1186/1475-2867-6-16 (Pubitemid 44070252)
39. Nagahara A., Nakayama M., Oka D., Tsuchiya M., Kawashima A., Mukai M., Nakai Y., Takayama H., Nishimura K., Jo Y., Nagai A., Okuyama A., Nonomura N., SERPINE2 is a possible candidate promotor for lymph node metastasis in testicular cancer. Biochemical and Biophysical Research Communications 2010 391 4 1641 1646 2-s2.0-74449087246 10.1016/j.bbrc.2009.12.105
40. Fayard B., Bianchi F., Dey J., Moreno E., Djaffer S., Hynes N. E., Monard D., The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression. Cancer Research 2009 69 14 5690 5698 2-s2.0-67651007506 10.1158/0008-5472.CAN-08-4573
41. Gao S., Krogdahl A., Sorensen J. A., Kousted T. M., Dabelsteen E., Andreasen P. A., Overexpression of protease nexin-1 mRNA and protein in oral squamous cell carcinomas. Oral Oncology 2008 44 3 309 313 2-s2.0-39049125070 10.1016/j.oraloncology.2007.02.009 (Pubitemid 351249194)
42. Yang S., Dong Q., Yao M., Shi M., Ye J., Zhao L., Su J., Gu W., Xie W., Wang K., Du Y., Li Y., Huang Y., Establishment of an experimental human lung adenocarcinoma cell line SPC-A-1BM with high bone metastases potency by 99mTc-MDP bone scintigraphy. Nuclear Medicine and Biology 2009 36 3 313 321 2-s2.0-62549110829 10.1016/j.nucmedbio.2008.12.007
43. Taniguchi K., Takeya R., Suetsugu S., Kan-o M., Narusawa M., Shiose A., Tominaga R., Sumimoto H., Mammalian formin Fhod3 regulates actin assembly and sarcomere organization in striated muscles. Journal of Biological Chemistry 2009 284 43 29873 29881 2-s2.0-70350350026 10.1074/jbc.M109.059303
44. Jurmeister S., Baumann M., Balwierz A., MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Molecular and Cellular Biology 2012 32 3 633 651
45. Blake J., Ziman M. R., Aberrant PAX3 and PAX7 expression. A link to the metastatic potential of embryonal rhabdomyosarcoma and cutaneous malignant melanoma? Histology and Histopathology 2003 18 2 529 539 2-s2.0-0037378004 (Pubitemid 36362071)
46. Kubic J. D., Young K. P., Plummer R. S., Ludvik A. E., Lang D., Pigmentation PAX-ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease. Pigment Cell and Melanoma Research 2008 21 6 627 645 2-s2.0-56249132134 10.1111/j.1755-148X.2008.00514.x
47. Schulte T. W., Toretsky J. A., Ress E., Helman L., Neckers L. M., Expression of PAX3 in Ewing's sarcoma family of tumors. Biochemical and Molecular Medicine 1997 60 2 121 126 2-s2.0-0031127217 10.1006/bmme.1997.2567 (Pubitemid 27198134)
48. Haga S. B., Fu S., Karp J. E., Ross D. D., Williams D. M., Hankins W. D., Behm F., Ruscetti F. W., Chang M., Smith B. D., Becton D., Raimondi S. C., Berg P. E., BP1, a new homeobox gene, is frequently expressed in acute leukemias. Leukemia 2000 14 11 1867 1875 2-s2.0-0033759191
49. Man Y. G., Fu S. W., Schwartz A., Pinzone J. J., Simmens S. J., Berg P. E., Expression of BP1, a novel homeobox gene, correlates with breast cancer progression and invasion. Breast Cancer Research and Treatment 2005 90 3 241 247 2-s2.0-17744368674 10.1007/s10549-004-4492-9 (Pubitemid 40576837)
50. Hara F., Samuel S., Liu J., Rosen D., Langley R. R., Naora H., A homeobox gene related to Drosophila distal-less promotes ovarian tumorigenicity by inducing expression of vascular endothelial growth factor and fibroblast growth factor-2. American Journal of Pathology 2007 170 5 1594 1606 2-s2.0-34250858105 10.2353/ajpath.2007.061025 (Pubitemid 47339304)
51. Schwartz A. M., Man Y. G., Rezaei M. K., Simmens S. J., Berg P. E., BP1, a homeoprotein, is significantly expressed in prostate adenocarcinoma and is concordant with prostatic intraepithelial neoplasia. Modern Pathology 2009 22 1 1 6 2-s2.0-58149175829 10.1038/modpathol.2008.168
52. Trinh B. Q., Barengo N., Naora H., Homeodomain protein DLX4 counteracts key transcriptional control mechanisms of the TGF- β cytostatic program and blocks the antiproliferative effect of TGF- β Oncogene 2011 30 24 2718 2729 2-s2.0-79958776867 10.1038/onc.2011.4
53. Sun Y., Lu X., Yin L., Zhao F., Feng Y., Inhibition of DLX4 promotes apoptosis in choriocarcinoma cell lines. Placenta 2006 27 4-5 375 383 2-s2.0-33645053511 10.1016/j.placenta.2005.03.007
54. Fu Y., Lian Y., Kim K. S., BP1 homeoprotein enhances metastatic potential in ER-negative breast cancer. Journal of Cancer 2010 1 54 62
55. Tomida S., Yanagisawa K., Koshikawa K., Yatabe Y., Mitsudomi T., Osada H., Takahashi T., Identification of a metastasis signature and the DLX4 homeobox protein as a regulator of metastasis by combined transcriptome approach. Oncogene 2007 26 31 4600 4608 2-s2.0-34447123918 10.1038/sj.onc.1210242 (Pubitemid 47037043)
56. Qiao Y., Jiang X., Lee S. T., Karuturi R. K. M., Hooi S. C., Yu Q., FOXQ1 regulates epithelial-mesenchymal transition in human cancers. Cancer Research 2011 71 8 3076 3086 2-s2.0-79954577486 10.1158/0008-5472.CAN-10-2787
57. Zhang H., Meng F., Liu G., Zhang B., Zhu J., Wu F., Ethier S. P., Miller F., Wu G., Forkhead transcription factor Foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis. Cancer Research 2011 71 4 1292 1301 2-s2.0-79951849322 10.1158/0008-5472.CAN-10-2825
58. Feuerborn A., Srivastava P. K., Küffer S., Grandy W. A., Sijmonsma T. P., Gretz N., Brors B., Gröne H. J., The Forkhead factor FoxQ1 influences epithelial differentiation. Journal of Cellular Physiology 2011 226 3 710 719 2-s2.0-78650658756 10.1002/jcp.22385
59. Kaneda H., Arao T., Tanaka K., Tamura D., Aomatsu K., Kudo K., Sakai K., De Velasco M. A., Matsumoto K., Fujita Y., Yamada Y., Tsurutani J., Okamoto I., Nakagawa K., Nishio K., FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. Cancer Research 2010 70 5 2053 2063 2-s2.0-77950219816 10.1158/0008-5472.CAN-09-2161
60. Pischon N., Mäki J. M., Weisshaupt P., Heng N., Palamakumbura A. H., N'Guessan P., Ding A., Radlanski R., Renz H., Bronckers T. A. L. J. J., Myllyharju J., Kielbassa A. M., Kleber B. M., Bernimoulin J. P., Trackman P. C., Lysyl oxidase (Lox) gene deficiency affects osteoblastic phenotype. Calcified Tissue International 2009 85 2 119 126 2-s2.0-69249217790 10.1007/s00223-009- 9252-8
61. Siddikuzzaman, Grace V. M., Guruvayoorappan C., Lysyl oxidase: a potential target for cancer therapy. Inflammopharmacology 2010 19 3 117 129 2-s2.0-78549265536 10.1007/s10787-010-0073-1
62. von Strandmann E. P., Senkel S., Ryffel G., Hengge U. R., Dimerization co-factor of hepatocyte nuclear factor 1/pterin-4 α -carbinolamine dehydratase is necessary for pigmentation in Xenopus and overexpressed in primary human melanoma lesions. American Journal of Pathology 2001 158 6 2021 2029 2-s2.0-0034971162 (Pubitemid 32545188)
63. Eskinazi R., Thöny B., Svoboda M., Robberecht P., Dassesse D., Heizmann C. W., Van Laethem J. L., Resibois A., Overexpression of Pterin-4a-carbinolamine dehydratase/dimerization cofactor of hepatocyte nuclear factor 1 in human colon cancer. American Journal of Pathology 1999 155 4 1105 1113 2-s2.0-2442763214 (Pubitemid 29488918)
64. He J., Pan Y., Hu J., Albarracin C., Wu Y., Jia L. D., Profile of Ets gene expression in human breast carcinoma. Cancer Biology and Therapy 2007 6 1 76 82 2-s2.0-33847131523 (Pubitemid 46294180)
65. Brenne K., Nymoen D. A., Hetland T. E., Trope C. G., Davidson B., Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival. Human Pathology 2012 43 4 496 505
66. Ferragud J., Avivar-Valderas A., Pla A., De Las Rivas J., de Mora J. F., Transcriptional repression of the tumor suppressor DRO1 by AIB1. FEBS Letters 2011 585 19 3041 3046
67. Bommer G. T., Jäger C., Dürr E. M., Baehs S., Eichhorst S. T., Brabletz T., Hu G., Fröhlich T., Arnold G., Kress D. C., Göke B., Fearon E. R., Kolligs F. T., DRO1, a gene down-regulated by oncogenes, mediates growth inhibition in colon and pancreatic cancer cells. Journal of Biological Chemistry 2005 280 9 7962 7975 2-s2.0-20044380128 10.1074/jbc.M412593200 (Pubitemid 40349694)
68. Prunier C., Hocevar B. A., Howe P. H., Wnt signaling: physiology and pathology. Growth Factors 2004 22 3 141 150 2-s2.0-5744224140 10.1080/08977190410001720860 (Pubitemid 39377906)
69. Xu H. T., Yang L. H., Li Q. C., Liu S. L., Liu D., Xie X. M., Wang E. H., Disabled-2 and Axin are concurrently colocalized and underexpressed in lung cancers. Human Pathology 2011 42 10 1491 1498 2-s2.0-79953770919 10.1016/j.humpath.2011.01.004
70. Karam J. A., Shariat S. F., Huang H. Y., Pong R. C., Ashfaq R., Shapiro E., Lotan Y., Sagalowsky A. I., Wu X. R., Hsieh J. T., Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Clinical Cancer Research 2007 13 15, part 1 4400 4406 2-s2.0-34547678149 10.1158/1078-0432.CCR-07-0287 (Pubitemid 47219706)
71. Hannigan A., Smith P., Kalna G., Lo Nigro C., Orange C., O'Brien D. I., Shah R., Syed N., Spender L. C., Herrera B., Thurlow J. K., Lattanzio L., Monteverde M., Maurer M. E., Buffa F. M., Mann J., Chu D. C. K., West C. M. L., Patridge M., Oien K. A., Cooper J. A., Frame M. C., Harris A. L., Hiller L., Nicholson L. J., Gasco M., Crook T., Inman G. J., Epigenetic downregulation of human disabled homolog 2 switches TGF- β from a tumor suppressor to a tumor promoter. Journal of Clinical Investigation 2010 120 8 2842 2857 2-s2.0-77955295090 10.1172/JCI36125
72. Tong J. H., Ng D. C., Chau S. L., So K. K., Leung P. P., Lee T. L., Lung R. W., Chan M. W., Chan A. W., Lo K. W., To K. F., Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer 2010 10, article 253 2-s2.0-77952989040 10.1186/1471-2407-10-253
73. Anupam K., Tusharkant C., Gupta S. D., Ranju R., Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis. World Journal of Gastroenterology 2006 12 37 6041 6045 2-s2.0-33750261993 (Pubitemid 44608486)
74. Martin J. C., Herbert B. S., Hocevar B. A., Disabled-2 downregulation promotes epithelial-to-mesenchymal transition. British Journal of Cancer 2010 103 11 1716 1723 2-s2.0-78650185120 10.1038/sj.bjc.6605975
75. Bagadi S. A. R., Prasad C. P., Srivastava A., Prashad R., Gupta S. D., Ralhan R., Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer. Breast Cancer Research and Treatment 2007 104 3 277 286 2-s2.0-34547757365 10.1007/s10549-006-9422-6 (Pubitemid 47231278)
76. Chao A., Lin C. Y., Lee Y. S., Tsai C. L., Wei P. C., Hsueh S., Wu T. I., Tsai C. N., Wang C. J., Chao A. S., Wang T. H., Lai C. H., Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2. Oncogene 2011 31 764 775 2-s2.0-79959736461 10.1038/onc.2011.269
77. Siegel P. M., Massagué J., Cytostatic and apoptotic actions of TGF- β in homeostasis and cancer. Nature Reviews Cancer 2003 3 11 807 820 2-s2.0-0242499448 (Pubitemid 37376979)
78. Grant S. L., Begley C. G., The oncostatin M signalling pathway: reversing the neoplastic phenotype? Molecular Medicine Today 1999 5 9 406 412 2-s2.0-0032810535 10.1016/S1357-4310(99)01540-3 (Pubitemid 29399990)
79. David E., Guihard P., Brounais B., Riet A., Charrier C., Battaglia S., Gouin F., Ponsolle S., Bot R. L., Richards C. D., Heymann D., Rédini F., Blanchard F., Direct anti-cancer effect of oncostatin M on chondrosarcoma. International Journal of Cancer 2011 128 8 1822 1835 2-s2.0-79951994543 10.1002/ijc.25776
80. Fossey S. L., Bear M. D., Kisseberth W. C., Pennell M., London C. A., Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC Cancer 2011 11, article 125 2-s2.0-79953787909 10.1186/1471-2407-11-125
81. Choi C., Kim D., Kim S., Jeong S., Song E., Helfman D. M., From skeletal muscle to cancer: insights learned elucidating the function of tropomyosin. Journal of Structurl Biology 2012 177 1 63 69
82. Mlakar V., Berginc G., Volavšek M., Štor Z., Rems M., Glavač D., Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genes DCN and TPM1 in colorectal cancer. BMC Cancer 2009 9, article 282 2-s2.0-70349868190 10.1186/1471-2407-9-282
83. Raval G. N., Bharadwaj S., Levine E. A., Willingham M. C., Geary R. L., Kute T., Prasad G. L., Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors. Oncogene 2003 22 40 6194 6203 2-s2.0-0142025131 10.1038/sj.onc.1206719 (Pubitemid 37281649)
84. Zhu S., Si M. L., Wu H., Mo Y. Y., MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). Journal of Biological Chemistry 2007 282 19 14328 14336 2-s2.0-34347266556 10.1074/jbc.M611393200 (Pubitemid 47100416)
85. Zhao Y., Xiong X., Sun Y., DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(betaTrCP) E3 ubiquitin ligase and regulates survival and autophagy. Molecular Cell 2011 44 2 304 316
86. Peterson T. R., Laplante M., Thoreen C. C., Sancak Y., Kang S. A., Kuehl W. M., Gray N. S., Sabatini D. M., DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009 137 5 873 886 2-s2.0-67349241955 10.1016/j.cell.2009.03.046
87. Yen C. H., Lu Y. C., Li C. H., Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinoma. Molecular Medicine 2012 18 1 286 296
88. Nagai M. A., Fregnani J. H. T. G., Netto M. M., Brentani M. M., Soares F. A., Down-regulation of PHLDA1 gene expression is associated with breast cancer progression. Breast Cancer Research and Treatment 2007 106 1 49 56 2-s2.0-34848901129 10.1007/s10549-006-9475-6 (Pubitemid 47498092)
89. Neef R., Kuske M. A., Pröls E., Johnson J. P., Identification of the human PHLDA1/TDAG51 gene: down-regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation. Cancer Research 2002 62 20 5920 5929 2-s2.0-0037108860 (Pubitemid 35204755)